key: cord-0756960-zat5effj
authors: Mastellos, D. C.; Pires da Silva, B. G. P.; Fonseca, B. A. L.; Fonseca, N. P.; Martins, M. A.; Mastaglio, S.; Ruggeri, A.; Sironi, M.; Radermacher, P.; Skendros, P.; Ritis, K.; Manfra, I.; Iacobelli, S.; Huber-Lang, M.; Nilsson, B.; Yancopoulou, D.; Connolly, E. S.; Garlanda, C.; Ciceri, F.; Risitano, A. M.; Calado, R. T.; Lambris, J. D.
title: Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy
date: 2020-08-21
journal: nan
DOI: 10.1101/2020.08.17.20174474
sha: dae14a118f660453e0428b7abaeaefa5cce40bf6
doc_id: 756960
cord_uid: zat5effj

Growing clinical evidence has implicated complement as a pivotal driver of COVID-19 immunopathology. Deregulated complement activation may fuel thrombotic microangiopathy and NET-driven immunothrombosis, thereby exacerbating cytokine-driven hyper-inflammation and multi-organ failure. Complement therapeutics have gained traction as candidate drugs for countering the detrimental consequences of SARS-CoV-2 infection. Whether blockade of terminal complement effectors (C5, C5a, or C5aR1) can elicit similar outcomes to upstream intervention at the level of C3 remains debated. Here we have compared the clinical efficacy of the C5-targeting mAb eculizumab with that of the compstatin-based C3-targeted drug candidate AMY-101 in small independent cohorts of severe, mainly non-intubated COVID-19 patients. Our exploratory study indicates that therapeutic complement inhibition abrogates COVID-19 hyper-inflammation. Both C3 and C5 inhibitors elicit a robust anti-inflammatory response, reflected by a steep decline in CRP and IL-6 levels, associated with marked lung function improvement and resolution of SARS-CoV-2-associated ARDS. C3 inhibition afforded broader therapeutic control in COVID19 patients by attenuating both C3a and sC5b-9 generation and preventing FB consumption. This broader inhibitory profile of anti-C3 treatment was associated with a more robust decline of neutrophil counts, a greater decline of median LDH levels and more prominent lymphocyte recovery within the first 7 days of treatment. These early clinical results offer important insight into the differential mechanistic basis and underlying biology of C3 and C5 inhibition in COVID-19. They point to a broader pathogenic involvement of C3-mediated pathways and set the stage for larger prospective trials that will benchmark these complement-targeting agents in COVID-19.

As the COVID-19 pandemic sweeps through the globe with an increasing death toll, pressing questions about its intricate immunobiology arise, pointing at the same time to the urgent need for effective therapeutic measures to combat the detrimental systemic consequences of this disease 1, 2, 3 . Although initially perceived as a disease that exclusively targets the respiratory tract of individuals infected by SARS-CoV-2, COVID-19 has evolved into a complex, multi-organ pathology with a plethora of thomboinflammatory manifestations in key vital organs, including the lungs, heart, liver, kidney, and brain 2 . The common denominator driving pathology in these organs appears to be an extensive and deregulated activation of innate immune pathways that leads to massive monocyte and neutrophil infiltration into infected tissues and to a disseminated thromboinflammatory response of the microvascular endothelium (thrombotic microangiopathy) 4, 5, 6 . This derailed inflammatory response, marked by a systemic increase in proinflammatory cytokines (known as cytokine storm) reflects a maladaptive host immune response to SARS-CoV-2 that is instigated by pathogen recognition systems, such as the complement cascade, which becomes overwhelmingly active in their attempt to thwart the infectious agent 5, 7 .

Complement dysregulation is emerging as a key driver of COVID-19 hyperinflammation, immunothrombosis and microvascular endothelial injury 5, 7, 8 . Systemic complement activation, predominantly via the lectin pathway (LP) and classical pathway (CP), is closely correlated with microvascular injury, platelet-neutrophil activation, and a NET-dependent, Tissue Factor (TF)-driven hypercoagulable phenotype that disseminates through the vascular bed of multiple organs 8 . Mounting clinical data have implicated deregulated complement and coagulation pathways as risk factors for adverse outcomes in COVID-19 9 . Increased C5a and sC5b-9 levels and prominent activation of the C5a-C5aR1 axis have been reported both in the infected lungs and systemically 10, 11, 12 . While these studies have propelled the clinical evaluation of terminal pathway therapeutics (anti-C5, C5a/C5aR1 blockade), key C3mediated processes that fuel monocyte/neutrophil-driven inflammatory damage, cytokine responses and TF-driven thrombophilia in COVID-19 remain operative 8 .

These include upstream C3 convertase activity, leading to C3b-opsonization and AP amplification via any of the triggering routes that SARS-CoV-2 infection engages.

Earlier studies in animal models of SARS-CoV infection underscored the pivotal role of C3 activation in the pathogenesis of SARS-CoV associated ARDS 13 . Given that C3 activation is the convergence point of all complement pathways, we hypothesized that All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 21, 2020. . https://doi.org/10.1101/2020.08.17.20174474 doi: medRxiv preprint C3 targeting may afford broader and more comprehensive therapeutic coverage in COVID-19-associated ARDS 5 .

Here we have performed a comparative assessment of key clinical and biochemical correlates in two small COVID-19 patient cohorts with SARS-CoV-2 associated ARDS treated either with the C3-based therapeutic AMY-101 (Amyndas) or with the C5targeting mAb eculizumab (Soliris, Alexion). Patients received AMY-101 within a compassionate use program, and eculizumab within a prospective phase I/II single arm clinical trial. Eculizumab is a clinically approved anti-C5 mAb that targets exclusively the terminal (lytic) pathway and its downstream effectors (C5a and MAC) 14 . AMY-101 is a C3-targeted drug candidate based on third-generation compstatins, a family of cyclic peptides that bind C3 and prevent its activation by C3 convertases.

AMY-101 and earlier compstatin analogs are currently in Phase II/III development, having shown safety in trials of chronic C3 intervention 15 .

While we acknowledge the inherent difficulty of testing these agents against a heterogeneous clinical background, especially in terms of reconciling disparate supportive measures or patient demographics, we have pursued a thorough investigation of the dynamic profile of changes in key disease markers during treatment with C3 and C5 inhibitors. This exploratory study has revealed both common and distinct clinical correlates and provides important insight into the underlying biology of complement inhibition in severe COVID-19.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in JAMA 2020) confirmed by a positive RT-PCR in the nasopharyngeal swab or tracheal lavage. All patients required oxygen support before treatment initiation; three eculizumab-treated patients were subjected to mechanical ventilation during therapy.

Patient demographics and clinical characteristics for both cohorts are presented in Table S1 (supplementary files). All COVID-19 patients received supportive care during anti-complement therapy including anticoagulants and broad-spectrum antibiotics (see Table S1 ). The Ecu-cohort also received concomitant treatment with corticosteroids according to physician's assessment. All ecu-patients received penicillin as prophylaxis during treatment.

Complement activity assay (APH50): Complement hemolytic activity via the alternative pathway (APH50) was monitored in all patient samples as previously described 16 . In brief, AP-mediated hemolytic activity was measured by the lysis of rabbit erythrocytes in the presence of patient sera dosed with the C3 and C5 inhibitors.

The degree of hemolysis was determined by spectrophotometric analysis of supernatants after centrifugation.

Complement protein levels and C3/C5 activation fragments: C3, C4, and FB levels were determined by nephelometry in patient plasma samples using an IMMAGE 800 protein chemistry analyzer (Beckman Coulter) C3dg levels were measured by nephelometry following PEG precipitation of patient plasma (11% w/v) and subsequent incubation with an anti-C3d antibody (Dako). C3a and sC5b-9 levels were measured in EDTA-plasma collected from the patients at predetermined time points by human C3a-and C5b-9 -specific ELISAs according to the manufacturer's instructions (Quidel). sC5b-9 levels were also determined using a modified ELISA method described in 17 .

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 21, 2020. . https://doi.org/10.1101/2020.08. 17.20174474 doi: medRxiv preprint To enable comparison of C5b-9 measurements derived from different laboratories and to normalize values generated from C5b-9 ELISA-based assays with different dynamic ranges of detection, we plotted the fold change of C5b-9 levels over baseline values for each patient/cohort.

Assay for IL-6: IL-6 levels were quantified in patient EDTA-plasma using an ELISA automated immunoassay (R&D Systems) following manufacturer's instructions.

Monitoring of AMY-101 levels in patient plasma: Quantitation of AMY-101 was performed in patient EDTA-plasma samples collected at predetermined time points during treatment by UPLC-ESI-MS as described previously 18 .

Assays for procoagulant markers: Thrombin-antithrombin complex (TAT) levels were quantified in patient EDTA-plasma using Enzygnost (TAT micro; Behringwerke, Marburg, Germany) as previously described 17 .

Statistical analysis: In view of the small sample size no formal comparisons for statistical significance were performed between the two patient cohorts. However, statistical analysis between two data sets (i.e., treatments, days) within the same group was performed using the unpaired (two-tailed) student's t-test (Prism, GraphPad v 8.0). The level of statistical significance was set to 0.05. Data are presented as mean values +/-standard deviation (SD).

Complement intervention has emerged as a promising strategy for ameliorating COVID-19 thromboinflammation. Consistent with this notion, compassionate treatment of a severe COVID-19 patient with the C3 therapeutic AMY-101 abrogated the hyperinflammatory phenotype associated with SARS-CoV-2, leading to respiratory improvement and resolution of ARDS 19 . Other reports have indicated that C5 inhibition or downstream C5a blockade may also benefit COVID-19 patients 20, 11, 21, 22 . While several complement therapeutics are advancing through the biopharma pipeline as potential COVID-19 anti-inflammatories, there has been no attempt to dissect the mechanistic basis of complement inhibition in COVID-19 or benchmark the efficacy of discrete anti-complement agents in COVID-19 patients.

Whether proximal (C3-based) or terminal (C5-based) complement inhibition may afford broader and sustained therapeutic effects in these patients remains the subject of ongoing investigation. Our exploratory study has assessed C3 and C5 inhibition in a All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 21, 2020. . https://doi.org/10.1101/2020.08.17.20174474 doi: medRxiv preprint series of severe COVID-19 patients, providing early evidence for a differential clinical response and drug efficacy that likely reflects distinct features of the underlying biology of C3 and C5 inhibition.

In the AMY-101 CUP, three patients were recruited from April 10 th to May 21 st , 2020.

Treatment was initiated in patients fulfilling the following criteria: COVID-19, diagnosed with qRT-PCR and chest X-ray and/or CT scan; ARDS, defined as acute-onset respiratory failure with bilateral infiltrates on chest radiograph or CT scan, hypoxemia as defined by a PaO2:FiO2 ratio ≤ 300 mm Hg with a positive end-expiratory pressure (PEEP) of at least 5 cm of H2O, and no evidence of left atrial hypertension to rule out cardiogenic edema; hyper-inflammation, defined as elevation of serum inflammation markers C-reactive protein (CRP ≥ 100 mg/L) and/or ferritin (≥ 900 ng/ml) (exclusion criteria listed in supplemental data).

In the eculizumab trial, patients meeting inclusion criteria were recruited from May 25 th to June 30 th , 2020. A total of 12 patients met criteria, but two refused to participate. A total of 10 patients gave written informed consent and were enrolled during this period of time. Two patients who were on mechanical ventilation before enrollment died of mechanical ventilation-associated pneumonia on days +19 (UPN1) and +18 (UPN9).

The other eight patients showed clinical improvement, were discharged, and are alive until last follow-up on August 12 th , 2020. One patient (UPN5) was intubated within 12 hours after the initial dose, required mechanical ventilation until day +9, and was discharged on day +17. All other patients did not require mechanical ventilation, but oxygen supplementation (nasal catheter, high flow oxygen mask), and were discharged on days +2 to +27 (median, 10 days). Three patients received one dose, three patients received two doses, and four patients received three doses of eculizumab. Eculizumab administration was halted when patients showed significant clinical improvement not requiring oxygen supplementation. Eight out of ten patients were alive and discharged at day +28. No severe adverse event (CTCAE grade III or IV) attributable to the drug was observed. Other severe adverse events are described in Table S2 (supplemental data).

inflammation. Both C3 and C5 inhibition elicited a robust anti-inflammatory response in COVID-19 patients marked by a rapid decline of C-reactive protein (CRP) levels that led to normalization with 6-8 days after treatment initiation. (Fig 1, panel A) . This rapid All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 21, 2020. . https://doi.org/10.1101/2020.08.17.20174474 doi: medRxiv preprint anti-inflammatory response also was reflected in a reciprocal decrease of IL-6 levels in AMY-101-and Ecu-treated patients that led to an almost 50% reduction of baseline values within 48 h from the start of treatment (Fig 1, panel C) . The pronounced tissue protective and anti-inflammatory effect of complement inhibition in COVID-19 patients was indicated by a significant reduction of LDH levels in both cohorts. Of note, AMY-101 treatment correlated with a steeper decline in LDH levels as compared to baseline values, in the first 7 days of treatment (Fig 1) . AMY-101 led to a 48.2% decrease of median LDH levels compared to 37.6% in non-intubated eculizumab-treated patients (n=7). 

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 21, 2020. . https://doi.org/10.1101/2020.08.17.20174474 doi: medRxiv preprint patients with a trend towards a greater increase in platelet counts between baseline (day 0) and day +8 in the AMY-101 cohort. While this finding indicates a likely more pronounced beneficial effect of C3 inhibition on platelet consumption early during the treatment, C5 blockade was also associated with a transient, albeit more moderate, increase in platelet counts during the same time window (Fig 2, panel C Treatment with eculizumab was associated with a dissimilar/divergent pattern of C5 blockade in COVID-19 patients. While sC5b-9 levels remained close to baseline values until day 2 (albeit with an upward trend), a significant rebound of sC5b-9 levels was observed on day 7 for most patients under eculizumab treatment (i.e., an almost 5-fold increase over baseline values) (Fig. 4, panel B ). This rebound might indicate a All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 21, 2020. . https://doi.org/10.1101/2020.08.17.20174474 doi: medRxiv preprint breakthrough in C5 inhibition, which could be due to suboptimal C5 blockade associated with overt complement activation (pharmacodynamic PD) and/or insufficient dosing of the drug. This observation follows up on recent reports indicating suboptimal C5 blockade in COVID-19 patients treated with eculizumab, under a similar dosing regimen (drug infusion once every 7 days) 22 . The reasons why sC5b-9

increases during eculizumab treatment, apparently diverging from clinical course, remain to be fully elucidated, but argue against using sC5b-9 as a reliable biomarker of disease activity in COVID-19.

Both inhibitors led to sustained inhibition of ex vivo AP-mediated complement hemolytic activity (AP50) in COVID-19 patient sera (Fig. 4, C) . While AMY-101 treatment resulted in complete abrogation of AP activity throughout the treatment, a residual hemolytic activity (ranging between 7-11.5%) was detected in patient sera dosed with eculizumab on days 2 and 7 respectively (Fig 4, C) . This 'leakage' in activity likely correlates with the rebound of terminal pathway activation products (sC5b-9) on While the concomitant use of steroids in the most severe Ecu-patients may have led to synergistic effects in lung function improvement 34 , the profound clinical gain observed under both inhibitory strategies paves the way to larger randomized trials that will formally benchmark the efficacy of these inhibitors in a well-controlled setting.

The persistently high C3a levels in the Ecu-treated patients confirmed that C5 blockade does not interfere with upstream C3 activation in COVID-19. A fully operative C3a-All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 21, 2020. . https://doi.org/10.1101/2020.08.17.20174474 doi: medRxiv preprint C3aR axis under C5 blockade could potentiate: i) monocyte/neutrophil recruitment to the infected lungs ii) cytokine release from macrophages and lymphocyte hyperactivation and iii) endothelial cell-platelet-neutrophil interactions promoting procoagulant responses, endothelialitis and TMA 35, 3 . This finding provides a mechanistic basis for a broader therapeutic effect of C3 inhibition in COVID-19 thromboinflammation. A trend towards lower median C3a levels in ecu-patients, on day 7 (approximately 35% decrease over baseline) (Fig 4, panel A) perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 21, 2020. . https://doi.org/10.1101/2020.08.17.20174474 doi: medRxiv preprint pathway activity, thereby preventing NET generation and subsequent thrombotic microangiopathies (supplemental Fig. 2) . Signs of ongoing AP activation in COVID-19 patients under C5 blockade may point to an amplifying role of the AP in driving complement-mediated pathology, regardless of initiating route. Furthermore, the rebound of C5b-9 levels in these patients warrants further investigation as it may reflect unique pathogenic events leading to excessive C5 activation or drug dosing-related issues. Possible accumulation of sC5b-9 due to reduced clearance compared to smaller-sized fragments, or other yet poorly defined mechanisms, cannot be ruled out, indicating that C5b-9 may not be a reliable biomarker for monitoring ongoing 

JDL is the founder of Amyndas Pharmaceuticals which develops complement inhibitors for therapeutic purposes, and inventor of patents that describe the therapeutic use of complement inhibitors, some of which are developed by Amyndas.

JDL is also the inventor of the compstatin technology licensed to Apellis Pharmaceuticals (i.e., 4(1MeW)7W/POT-4/APL-1 and PEGylated derivatives such as APL-2/pegcetacoplan and APL-9). A.M.R. has received research support from Alexion All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 21, 2020. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 21, 2020. 

Roche's Actemra Misses the Mark in Phase III COVID-19 Associated Pneumonia Study | BioSpace.

All rights reserved. No reuse allowed without permission.

perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted August 21, 2020. . https://doi.org/10.1101/2020.08.17.20174474 doi: medRxiv preprint perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 21, 2020. . https://doi.org/10.1101/2020.08.17.20174474 doi: medRxiv preprint perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 21, 2020. . https://doi.org/10.1101/2020.08. 17.20174474 doi: medRxiv preprint Time to no O 2 support Fi0 2 oxygen supplementation immunopathology and neutrophil-driven NETosis appears to be a key disease-exacerbating mechanism cross-linked with all other pathogenic events. Indeed, complement activation may trigger NETs generation, which in turn amplifies complement activation, thereby enhancing inflammation and thrombophilia. Complement activation, cytokine-driven inflammation, NETosis and thrombophilia are closely embedded in the pathophysiology of COVID-19, and therapeutic interventions aiming to 'defuse' this detrimental loop need to interfere with early pathogenic events, such as proximal complement activation, preceding the tissue damage associated with thrombo-inflammation.

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Extrapulmonary manifestations of COVID-19

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases

Complement as a target in COVID-19?

Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications

The complement system in COVID-19: friend and foe?

Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis

Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection

Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis

Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria

Clinical promise of next-generation complement therapeutics

Use of serum or buffer-changed EDTA-plasma in a rapid, inexpensive, and easy-to-perform hemolytic complement assay for differential diagnosis of systemic lupus erythematosus and monitoring of patients with the disease

Incompatibility between human blood and isolated islets of langerhans: A finding with implications for clinical intraportal islet transplantation?

Method development and validation for the quantitation of the complement inhibitor Cp40 in human and cynomolgus monkey plasma by UPLC-ESI-MS

The first case of COVID-19 treated with the complement C3 inhibitor AMY-101

Eculizumab treatment in patients with COVID-19: Preliminary results from real life ASL Napoli 2 Nord experience

Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study

Complement C5 inhibition in patients with COVID-19 -a promising target?

Haematological characteristics and risk factors in

Myocarditis 3 None of the severe adverse events were likely to be attributable to the study drug.